Small molecule screening, the systematic encounter of biology space with chemical space, has provoked the emergence of a whole industry that recreates itself by constant iterative improvements to this process. The authors describe an approach to tackle the problem for one of the most time-consuming steps in the execution of a screening campaign, namely, the reformatting of high-throughput screening test compounds from master plates to daughter assay plates used in the execution of the screen. Through an engineered storage procedure, they prepare plates ahead of the screening process with the respective compounds in a ready-to-use format. They show the biological inertness of the method and how it facilitates efficient recovery of compound activity. This uncoupling of normally interconnected processes provides time and compound savings, avoids repeated freeze-thaw cycles of compound solutions, and removes the problems associated with the DMSO sensitivity of certain assays types. (Journal of Biomolecular Screening 2005:573-580) 
INTRODUCTION
T HROUGHOUT THE EXECUTION of a screening campaign on any given platform, processing of high-throughput screening (HTS) compounds requires substantial amounts of time. 1 The basic premise of the NanoStore concept is to uncouple the compound handling procedure from the rest of the screening campaign, in terms of the time frame. Using this approach, HTS compounds can be reformatted into screening plates in a ready-to-use manner days, weeks, or even months ahead of the screen execution. The methodology we describe here for achieving this requires, in contrast to common state-of-the-art screening processes, a compound dry-down step as a key logistical feature.
The process of drying compounds down (actively removed from the solution onto the surface of the plate well) in microplates is subject to the risk of poor recovery efficiencies. This is especially true for those compounds with hydrophobic properties, due to surface adsorption and redissolution issues in aqueous buffers. In addition, when using high-density plates (1536 wells or higher formats), these problems are likely to be exacerbated due to the increased surface area-to-volume ratio of these wells. One method that can be used to minimize this risk is the use of chemical additives that prevent adsorption and promote efficient and rapid redissolution of compounds upon addition of screening reagents. The data described in this article show that precoating of plates with distinct excipients can facilitate resolubilization of compounds with diverse molecular properties once they have been dried down. Following selection of the most suitable excipient, we have optimized the procedure for this compound storage concept. Compound recovery is demonstrated here by analytical methods (liquid chromatography/mass spectrometry [LC/MS]) as well as by direct comparison of their biochemical activity in distinct assays whether actively dried down or not. At the same time, we show that the optimal excipient, 2-hydroxypropyl-β-cyclodextrin (HBC) 2 is inert in a wide range of biological assay types. In addition, the generation of multiple screening plates from a single compound master plate reduces repeated freeze/thaw cycles of compound solutions, a process that is known to adversely affect the integrity of many compounds in solution. 3, 4 Finally, the applied dry-down procedure entirely removes the DMSO in which the test compounds are usually dissolved, therefore, in turn, eliminating any DMSO sensitivities certain assays exhibit. [5] [6] [7] [8] The method as outlined here, which we have termed the NanoStore concept, provides major logistical and therefore economical improvements to the HTS process without compromising the biology assay scope and is used routinely in our laboratories. 9
MATERIALS AND METHODS

Excipients
The following agents were used for plate coating: HBC, a substituted cyclodextrin consisting of 7 carbohydrate residues (SIGMA, H-107), degree of substitution 0.6 to 0.8 hydroxypropylgroups per glucose unit; Biostab, a mixture of amino acids isolated from several microorganisms, (e.g., ectoine, hydroxyectoine, betaine, N-actetyl-lysine, L-carnitine, and Lproline; Bitop GmbH, Witten, Germany) 10 ; Firoin α-Dmannosylglycerate, a carbohydrate isolated from thermophilic bacteria (Rhodothermus marinus; Firoins are especially known to protect biomolecules from thermal denaturation (Bitop GmbH, Witten, Germany); DOPC (1,2-Di (cis-9-octadecenoyl)-snglycero-3-phosphocholine; phosphocholine is often used for the preparation of unilamellar liposomes in studies with fluorescent membrane probes (SIGMA, P6354); and Pluronic F-127, a nonionic detergent useful for solubilizing dye molecules with proven cell compatibility (SIGMA, P2443). All other reagents used in this study were purchased from Sigma/Aldrich unless otherwise indicated. Excipients were chosen to achieve a compromise between the amphiphilic nature of the excipient, the caging properties under low salt conditions, the biological inertness, and the former use in galenic applications.
Preparation of precoated screening plates
The wells of a NanoCarrier™ 1536 plate (Evotec Technologies GmbH, Hamburg, Germany) were automatically filled with 3 µL of one of the following aqueous, filtered (0.22 µm) solutions using a Cartesian SynQuad device (Genomic Solutions, Ann Arbor, MI): 1) 0.2% (w/v) HBC, 2) 0.2% Biostab (w/v), 3) 0.0015% DOPC (v/v), 4) 0.1% Pluronic F-127 (v/v), and 5) 0.2% Firoin (w/ v). Evaporation of the solvent was performed at 20°C for 24 h in a dust-free atmosphere.
Compound loading, dry down, and recovery
The compound-loading process resembles the preparation of plates for a typical biochemical screen but with an additional drydrown procedure. Nanoliter volumes of compounds dissolved in neat DMSO were dispensed by piezoelectric-driven benchtop fluidic devices from Evotec Technologies GmbH (Hamburg, Germany), whereas microliter volumes were dispensed by a Cartesian SynQuad device. Compounds were dried down under reduced pressure at 30°C for 20 min using a specially designed evaporating device (Barkey GmbH & Co. KG, Leopoldshöhe, Germany). Prepared plates were stored afterward without plate sealing in a dustfree atmosphere. The work flow was as depicted in Figure 1 .
Compound recovery as investigated by LC/MS
This study used 15 known drugs ranging from 293 to 608 in molecular weight and with clog P values ranging from 2.09 to 5.34. The compounds were subjected to the dry-down procedure as described for dose-response generation. A total of 5 wells per compound and per dry-down condition were investigated in this recovery study. Each NanoCarrier™ contained samples with both dry-down conditions (precoated with excipient and nonprecoated but excipient present). To avoid LC/MS calibration studies for each of the 5 excipients, with every test compound, the compound dilution buffer in the LC/MS study contained all 5 excipients at the relevant concentration. This reduced the calibration studies to 1 Work flow for compound loading, dry-mode procedure and recovery. Evaporation was performed at 32/34°C for 1 h at reduced pressure. Dried-down compounds were recovered in 3 µL of a typical assay buffer (50 mM HEPES, 50 mM NaCl, 0.1% Pluronic F-127, pH 7.4) and incubated for 1 h at 20°C in a humid atmosphere to prevent any evaporation. Finally, 2.7 µL of the recovered compound solution was removed manually and diluted to 30 µL in dilution buffer (50 mM HEPES, 50 mM NaCl, 0.1% Pluronic F-127, 0.2% 2-hydroxypropyl-β-cyclodextrin, 0.2% Fiorine, 0.2% Biostab, pH 7.4). The rationale for the composition of the dilution buffer is given in the next section. Of that solution, 27 µL was manually removed to load the sample holder of the liquid chromatography/mass spectrometry (LC/MS) device (Waters Micromass, Milford, MA); 20 µL was used for injection and analysis. calibration curve per compound. Single ion recording was applied for compound quantification to prevent any effect of excipients on the analytical result. Only characteristic masses of the accordant compounds were detected. A further advantage of this technique was the improved sensitivity and accuracy. The LC/MS studies were carried out on a Waters 2690 Separations module connected to a Jetstream 2 plus column oven, Waters 996 photo diode array detector, Waters FD 474 fluorescence detector, and a Micromass ZMD mass spectrometer (Waters GmbH, Eschborn, Germany).
The following chromatographic conditions were used:
Column: Waters Symmetry™ C18 3.5 µm, 2.1 × 30 mm with Waters Symmetry™ C18 3.5 µm 2.1 × 10 mm guard column Eluent: (A) H2O/0.1% HCO2H, (B) methanol/0.1% HCO2H Flow rate: 0.5 mL/min Gradient: time (%A/%B); 0.00 min (90/10); 3.00 min (2/98); 3.75 min (2/98); 8.00 min (90/10) MS detection: ESI plus traces → single ion recording Ultraviolet/vis detection: 200 nm to 798 nm, resolution 1.2 nm, 1 spectra/s
Biochemical reagents required for assays used to investigate compound recovery
The FRET peptide substrate for the neutral endopeptidase assay (NEP) was synthesized in house (cf. international patent reference WO 02/06492 A1). NEP was prepared as follows: The extracellular domain of human NEP (residues 52-749) was cloned into pPICZα, transformed into Pichia pastoris GS115, and NEP production induced by using a methanol carbon source. Induction was maintained for 120 h prior to harvesting by centrifugation. The cells were then discarded, and the supernatant was concentrated using a Millipore 10K cutoff cassette. Media salts and secondary metabolites were removed by diafiltration against 50 mM Tris buffer (pH 7.0), and the concentrated protein was passed through a DEAE Sepharose column. The flow through was then applied to a phenyl sepharose column, and an ammonium sulphate gradient was applied. The NEP eluted at about 10% ammonium sulphate saturation. Finally, NEP was dialyzed against 50 mM Tris (pH 8.0), applied to a Resource Q column, and eluted with 50 mM NaCl. Western blot and MS were used to confirm identity. Typically, the enzyme was about 90% pure as judged by MS and SDSpolyacrylamide gel electrophoresis. The reagents used for the β 2adrenergic receptor (β 2 -AR) were as described previously. 11
Assay formats
The NEP assays were performed in 50 mM HEPES buffer, pH 8.0, containing 0.1% (v/v) Pluronic-F127 and 1% (v/v) protease inhibitor cocktail (antipain, aprotinin, leupeptin, pepstatin A) in either noncoated or HBC precoated 2080-well NanoCarriers™ (Evotec Technologies GmbH, Hamburg, Germany) to give a final HBC concentration of 0.2% (w/v). Enzyme reactions were typically at about 10 nM NEP and initiated by the addition of 1 µM substrate. Plates were then incubated at 25°C for 1 h prior to termi-nation with 10 µM thiorphan. Activity was determined via measurement of the increase in count rate with laser excitation at 546 nM, using the Evotec FCS++ confocal reader (Evotec Technologies Gmbh, Hamburg, Germany) in non-single molecule mode. The β 2 -AR assay format was as previously described. 11 The drymode low-volume assay was performed as for NEP, using the MkII Evoscreen system, whereas wet-mode low-volume assays were performed on an Evotec Assay Development Station (Insight Reader, MONA and DINA; Evotec Technologies GmbH, Hamburg, Germany).
Dose-response generation and data analysis
For dry-mode experiments, compound concentrations ranging from 200 µM to 10 nM in 5% or 70% DMSO solutions were added to HBC precoated 2080-well NanoCarriers™, and the liquid was actively evaporated at 0.2 Bar for 15 min at 30°C. Plates were prepared at least 24 h before experiments were carried out and stored at 4°C in low (<10%) humidity. In the case of wet mode (i.e., compound transfer just ahead of the screen), plates were assayed immediately after reformatting (visual inspection confirmed that the compound droplet integrity was maintained).
NEP IC 50 values were determined from 12-point serial 2-fold dilutions created using a Tecan Genesis robot (Tecan-UK, Reading, United Kingdom) from a top concentration of 100 µM final. Each IC 50 was determined n = 6, and IC 50 values quoted are the mean and standard deviation of log 10 of the measurements. Three different experimental conditions were tested, specifically, dry mode (+HBC, no DMSO), wet mode (DMSO only), and wet mode with HBC added. IC 50 data analysis was carried out using an inhouse Excel macro. Correlation coefficients were calculated using Grafit 4 (Erithacus Software Ltd, Surrey, United Kingdom). Assay performance was quantified via calculation of Z′ from control wells. 12 β 2 -AR IC 50 values were determined from 8-point serial half-log dilutions from a top concentration of 10 µM final. Each IC 50 was determined n = 4, and IC 50 values quoted are the mean and standard deviation of log 10 of the values. Two different experimental conditions were tested: dry mode (+HBC, no DMSO) and DMSO only (wet mode). IC 50 data analysis was carried out using a GraphPad Prism (GraphPad Software, Inc., San Diego, CA). Assay performance was quantified via calculation of Z′ from control wells. 12 mlog P values were calculated using the method of Moriguchi et al, 13 and clog P values were calculated as described by Leo. 14 
RESULTS
Analytical investigations
The data in Table 1 indicate that of the 5 excipients investigated, HBC emerged from this study as the best for compound recovery, with 8 of 15 compounds recovered by more than 60% (mean recovery overall was 56%). Biostab was the next best, with 6 compounds recovered by more than 60% (mean recovery of 45%).
Based on the 5 wells per compound investigation, the calculated percentage coefficient of variability (CV) was below 15% for 73% of all samples, which validates the analytical method. However, at the same time, this does indicate some sample-handling errors in the miniaturized format, as do the relatively wide standard deviations observed for most of the dry-mode data. Although there is no correlation between the molecular weight of a compound and its recovery, there is an expected tendency toward less recovery with increasing clog P values; however, there are exceptions to the rule, as demonstrated by bisacodyl, for example.
Observations from multiple HTS campaigns have shown that addition of detergent such as Pluronic F-127 to the assay buffer can significantly enhance the robustness and performance of fluorescence assays, presumably due to amelioration of fluor-ligand binding to plate materials. To determine the effect of detergent on the resolubilization process, we performed a dry-mode experiment with the compounds pramoxine, loperamide, and mifepristone, resolubilizing in buffers in the presence and absence of detergent. The data are summarized in Table 2 and indicate that Pluronic F-127 did not have a deleterious effect on compound resolubilization and indeed, in contrast, appeared to have been beneficial, particularly in the case of the high clog P compounds. These 3 compounds were also employed in a study testing the resolubilization kinetics. To mimic time points for reagent and compound distribution for a typical screen on an integrated HTS platform, we determined the amount of resolubilized pramoxine, loperamide, and mifepristone after 20, 30, 40, 60, 90, and 120 min. We did not observe any major differences in the degree of compound recovery at these times, consistent with a stable solubility equilibrium for all compounds within 20 min when HBC precoated plates and Pluronic-containing assay buffers were used (data not shown).
Recovery of biological compound activity
To further explore the utility of the excipient HBC in HTS, we conducted a series of experiments using biological assays. The aim was to use the biological assays as a probe for compound concentration. The assays were chosen to be amenable to HTS, facilitating the generation of data volumes from which statistical confidences could be calculated. Compounds with known activity against specific targets were tested in dry mode and also under normal screening conditions. The compounds were chosen to represent as broad a range of chemical properties as possible. This allowed a judgment to be made on the recovery of biological activity of dried-down compounds as well as the detection of any potential structural bias of the excipient. Two biochemical assays were chosen for this study based on the diversity of inhibitor/antagonists/agonists (wide potency range and diverse molecular properties) that exist for these assay targets. Specifically, the assays used were the inhibition of NEP and the competitive binding of compounds to the human β 2 -adrenergic G protein-coupled receptor (β 2 -AR). Thirty-nine compounds were subjected to the NEP assay in dry mode on HBC precoated 2080-well NanoCarriers™ and compared to normal screening conditions (wet mode). In the case of β 2 -AR, 12 compounds were compared in a similar fashion. Figure 2 shows the distribution of mlog P and molecular weight for these compounds.
Assay performance
Overall assay performance was satisfactory, with up to 80% of NEP and 100% of β 2 -AR assay data passing the quality control criteria of Z′ > 0.4 (data not shown).
Effects of HBC on low-volume wet-mode screening
Interaction between compounds and HBC has the potential to reduce the free solution concentration of well-solvated compounds, which may affect assay sensitivity. To define the extent of this risk, we therefore measured the test compound IC 50 values in low-volume wet-mode conditions in the presence and absence of 0.2% (w/v) HBC. The results are shown in Figure 3 . Both conditions ±HBC, wet mode, gave very similar results (within experi- mental error), with 97% of the compounds repeating having IC 50 values within 3-fold and 100% within 5-fold. The correlation coefficient was 0.9, with a slope of 0.8 ± 0.06. These data are consistent with HBC having no significant effect on the observed potency of the compounds.
Influence of NanoStore on the potency of compounds
To evaluate the effect of dry down on compound concentration, we measured the IC 50 values of a range of compounds using lowvolume wet mode and dry mode. The data are summarized in Figure 4 for NEP (A) and β 2 -AR (B). Examples of the types of compounds used are illustrated in Table 3 . For the 39 NEP compounds with IC 50 values <15 µM in wet mode using the Evoscreen system, 2 failed to repeat in dry mode. The reason for lack of recovery of these compounds is not clear, and further investigation is required to elucidate this. However, of the remaining compounds, 36 of 37 (97%) generated IC 50 values within 5-fold and 34 of 37 (92%) within 3-fold for the dry-mode versus wet-mode conditions, respectively. As shown in Figure 4A , the correlation coefficient between these 2 conditions (dry mode vs. wet mode) was 0.9 with a slope of 0.8 ± 0.07, indicating that dry mode did not appear to have a significant attenuating effect on observed compound potency (cf. wet mode ±HBC, where the slope was 0.8 ± 0.1; Fig. 3 vs. Fig.  4A) . A similar analysis of the 12 β 2 -AR antagonists/agonists demonstrated that the IC 50 values for 7 of 12 compounds (58%) were within 3-fold and 10 of 12 (83%) were within 5-fold for the drymode versus wet-mode conditions, respectively. The correlation coefficient between the 2 β 2 -AR data sets was 0.9 with a slope of 0.8 ± 0.1 (Fig. 4B ). Taken together, these data indicate that dry mode is a viable form of screening operation for compounds with a range of mlog P and molecular weight properties. To establish the general impact of HBC on biological assays, we also tested the effect of this excipient up to 0.2% (w/v) on the performance of >50 in vitro assays of various types (Fig. 5 ). We have found that up to and often exceeding 0.2% (w/v), the vast majority of assays are not significantly affected by HBC; indeed, in many cases, HBC often increases assay robustness.
DISCUSSION
To facilitate the uncoupling of HTS compound handling and reformatting from the screening process, we have devised a procedure to produce, store, and reactivate ready-to-use HTS assay plates containing compounds. To achieve this optimally, we used 1536-well and 2080-well plates precoated with HBC excipient. The HBC was found to be beneficial for effective compound resolubilization for the assay and has negligible or no detrimental effect on the assay robustness and performance. The temporal and potential spatial separation of compound handling and screening accelerates and simplifies the logistics of the HTS process significantly. This procedure also makes best use of compound daughter plates and entirely removes DMSO sensitivities for certain assay systems.
HBC was identified as an agent for effectively enabling compound dry down and resolubilization (NanoStore) over and above a selection of other excipients (Table 1) . Moreover, using 2 biochemical assays as probes, we found that the vast majority of compounds with a range of molecular properties could be recovered to give IC 50 s that correlated with control data within statistical error. Of the total of 51 compounds evaluated, 2 (3.9%) were not recovered. Although this is a potential concern, our view is that the NanoStore method is an acceptable compromise; the method affords enabling logistical and cost benefits while allowing the identification of the vast majority of chemical series with good properties.
The mode of action for HBC is not fully clear at this point. Although HBC is known to be an effective compound caging agent, 15, 16 This is also confirmed by the diverse chemical nature of the various active compounds we consistently recovered in this study. In previous studies, we identified that the precoating of plates with a volume sufficient to coat the entire well surface provided superior data compared to mixing HBC into the compound solution. We assume, therefore, that HBC forms a film on the inside of the plate wells, thereby saturating hydrophobic interactions with the plastic material and providing a hydrophilic surface to the solution in the well. In consequence, compounds with high mlog P values are less readily adsorbed, and resolubilization by assay buffer is enhanced. Several logistical advantages can be gained from the preparation of multiple HTS assay plates from a single master plate, reducing the need for repeated freeze/thaw cycles of the master plate (which may enhance the effective lifetime of the compounds) and also enabling multiple copies of the daughter assay plates to be generated and "NanoStored" until required for HTS. In addition, because of the complete separation of compound preparation from the screening process, assay plates can be prepared at a different site from the screening process. This could be especially useful for large organizations in which compound reformatting and supply are often geographically separated from the screening process.
The NanoStore concept has been developed for biochemical screens, and it could also be used for cellular assays if suspension cells are used. In this case, it would be good practice to incorporate an HBC sensitivity screen as an integral part of assay development for biochemical and cellular screens, in a similar fashion to the assessment of DMSO-tolerance of assays.
CONCLUSIONS
This study has demonstrated that a diverse population of active compounds in an enzyme and receptor-ligand binding assay can be detected post dry down using the NanoStore approach. The primary benefit of NanoStore is the increase in operational efficiency that is achieved by decoupling compound handling from the HTS assay process in miniaturized HTS protocols. Further efficiencies related to maximizing the efficiency of compound use might also be achieved by preparing multiple copies of plates for different screening campaigns in a single reformatting session. 
